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Background: Available definition criteria for metabolic syndrome (MS) have similarities and inconsistencies. The aim
of this study was to determine the prevalence of MS in a group of Cameroonians with type 2 diabetes, according
to the International Diabetes Federation (IDF) and the National Cholesterol Education Programme Adult Treatment
Panel III (NCEP-ATP III) criteria, and to assess the concordance between both criteria, and the implications of
combining them.
Methods: We collected clinical and biochemical data for 308 patients with type 2 diabetes (men 157) at the
National Obesity Center of the Yaounde Central Hospital, Cameroon. Concordance was assessed with the use of the
Kappa statistic.
Results: Mean age (standard deviation) was 55.8 (10.5) years and the median duration of diagnosed diabetes (25th–75th
percentiles) was 3 years (0.5–5.0), similarly among men and women. The prevalence of MS was 71.7% according to the
IDF criteria and 60.4% according to NCEP-ATP III criteria. The prevalence was significantly higher in women than in men
independently of the criteria used (both p< 0.001). Overall concordance between both definitions was low to average
0.51 (95% confidence interval: 0.41–0.61). Combining the two sets of criteria marginally improved the yield beyond that
provided by the IDF criteria alone in men, but not in the overall population and in women.
Conclusions: The IDF and NCEP-ATP III criteria do not always diagnose the same group of diabetic individuals with MS
and combining them merely increases the yield beyond that provided by the IDF definition alone. This study highlights
the importance of having a single unifying definition for MS in our setting.
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Metabolic syndrome (MS) is a group of clinical and
biological abnormalities that confers a greater risk of type
2 diabetes, cardiovascular (CVD) [1] and liver diseases [2].
The different components of MS were initially described
by Reaven in 1988 under the appellation of “syndrome X”
[3]. These include abdominal obesity, higher-than-optimal
blood pressure, disorders of glucose metabolism and ab-
normal lipid profile [4]. Although still debated, the under-
lying feature of all these abnormalities seems to be insulin
resistance [5]. Regardless of the presence of any abnormal-
ities of glucose metabolism, individuals with MS are at* Correspondence: apkengne@yahoo.com
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reproduction in any medium, provided the orincreased risk of type 2 diabetes [6]. The co-occurrence of
diabetes mellitus and MS potentiates the cardiovascular
risk associated with each of the two conditions. Character-
izing MS in the presence of diabetes is therefore beneficial
for the purpose of cardiovascular prevention. However,
instruments for diagnosing MS are likely to vary
substantially.
Over the last decade, several sets of criteria have been
suggested for the diagnosis of MS. These include the cri-
teria by the World Health Organization (WHO, 1998)
[7], the European Group for study on insulin Resistance
(EGIR) in 1999 [8], the National Cholesterol Education
Program Adult Treatment Panel III (NCEP-ATP III) in
2001 [9] and the International Diabetes Federation (IDF)
in 2005 [4]. These criteria share common ground in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kengne et al. Diabetology & Metabolic Syndrome 2012, 4:22 Page 2 of 8
http://www.dmsjournal.com/content/4/1/22sense that they all acknowledge disorders of glucose
metabolism, hypertension, dyslipidaemia and obesity as
components of metabolic syndrome. They also have
areas of inconsistencies, particularly regarding the
threshold levels for defining the abnormalities and how
these should be combined to define metabolic syndrome.
The implication of these inconsistencies is that the yield
of various criteria may vary significantly in the same
population. This can have potentially undesirable conse-
quences for risk stratification and prioritization of
patients for preventive treatment. For instance, a patient
may be denied such treatment on the basis of one set of
criteria, why he would be eligible using a different set of
criteria.
We are not aware of studies at the national or regional
level that have assessed and compared the output of vari-
ous criteria for defining MS in people with diabetes in sub-
Saharan Africa. The growing population of individuals
with diabetes in the region invites reliable tools to backup
strategies for improving their cardiovascular health [10].
Accordingly, the aim of this study therefore was to assess
the concordance of two sets of definition criteria for MS in
a population of individuals with type 2 diabetes in
Cameroon.
Results
Characteristics of the study population
A total of 308 type 2 diabetic participants were recruited,
with nearly equal number of men and women. The mean
age (standard deviation: SD) of participants was 55.8 (10.9)
years, and the median known duration of diabetes was 3.0
(25th–75th percentiles: 0.5–5.50) years, with no significant
difference between men and women. The mean levels of
systolic and diastolic blood pressures and prevalence of
hypertension were also similar between men and women
(Table 1). The mean body mass index (BMI) was higher in
women than in men (28.8 vs. 27.0 kg/m2; p< 0.001), while
the prevalence of current smokers was higher in men than
in women (8.3% vs. 1.3%; p=0.003), (Table 1).
The biological profile of the study population overall
and for men and women is summarized in Table 1. HDL
cholesterol level was significantly higher in women than
in men (p= 0.04) while post-prandial glycaemia was
significantly higher in men than in women (p= 0.04). No
significant difference was noted elsewhere.
Oral anti-diabetic medications were been taken by 222
(72.1%) patients; while 78 (25.3%) were on insulin and 26
(8.4%) patients on both. No patient was on diet alone.
More women than men were on either insulin alone, or
in association with oral agents (both p= 0.04). One hun-
dred and thirty eight (44.8%) were on blood pressure
lowering treatments, similarly among men and women
(p= 0.22). Only 1% of participants were on statin or as-
pirin (Table 1).Crude and age adjusted prevalence of metabolic
syndrome
According to the IDF criteria 221 (crude prevalence:
71.7%) participants had metabolic syndrome. The corre-
sponding figures for the NCEP-ATP III criteria were 186
(60.4%), Table 2. The prevalence was significantly higher
in women than in men independently of the criteria used
(both p< 0.001). The age-adjusted prevalence of MS was
64.5% (overall), 55.7% (men) and 72.1% (women) accord-
ing to the IDF criteria. The corresponding figures for the
NCEP-ATP III definition were 55.6%, 43.1% and 68.1%
respectively.
There was a significantly increasing trend in the preva-
lence of MS by increasing age according to the IDF cri-
teria in the overall group (p= 0.03), and in women
(p= 0.02), but not in men (p= 0.78) (Table 2). The preva-
lence of MS was not significantly different across in-
creasing age strata overall (p= 0.21), and in men
(p= 0.80) and women (p= 0.28) respectively according to
NCEP-ATP III definition. With the exception of the age
stratum <45 years, the prevalence of MS within age
group was always higher in women than in men using ei-
ther criteria.
Agreement between sets of criteria
The overall concordance between both definitions was
0.51 (95% confidence interval: 0.41–0.61) overall, 0.33
(0.19–0.47) in men and 0.66 (0.50–0.82) in women. The
concordance statistics varied across age groups in an un-
predictable fashion in the overall group and in men and
women (Table 3). But the confidence interval about the
kappa statistics between age groups always overlapped,
suggesting that differences if any, were likely meaningless.
Cross classification in study population
Crossed classification of participants based on the two
sets of criteria is depicted in Figure 1. At the level of the
overall population, 80% of participants classified as not
having MS by the IDF criteria were also classified within
this category by the NCEP-ATP III criteria, while NCEP-
ATP III reclassified the 20% remaining as having MS.
Among those diagnosed with MS on the basis of the IDF
criteria, the NCEP-ATP III criteria confirmed the diag-
nosis of MS in 76% and reclassified 24% as not having
MS (Figure 1). Among men classified as not having MS
using the IDF definition, 23% were reclassified as having
MS, while among those diagnosed with MS on the basis
of the IDF criteria, 43% were reclassified as not having
the syndrome by the NCEP-ATP III criteria. In women
10% of participants without MS based on the IDF defin-
ition were reclassified as having the syndrome using the
NCEP-ATP III definition, while 10% with the syndrome
were further reclassified as not having the syndrome by
the NCEP-ATP III definition. Nearly similar pattern of







Mean age, years (SD) 55.6 (10.1) 56 (10.9) 0.74 55.8 (10.5)
Known duration of diabetes* 3.0 (0.5-5.0) 3.0 (0.5-5.0) 0.46 3.0 (0.5-5.0)
Mean BMI, kg/m2 (SD) 27.0 (4.2) 28.8 (5.0) <0.001 27.9 (4.7)
Mean waist circumference, cm (SD) 95.9 (9.6) 97.4 (11.0) 0.20 96.6 (10.4)
Mean systolic blood pressure, mm Hg (SD) 142.9 (24.5) 142.8 (25.2) 0.95 142.7 (24.8)
Mean diastolic blood pressure, mm Hg (SD) 84.3 (11.9) 83.0 (11.8) 0.37 83.7 (11.9)
Hypertension, n (%) 84 (53.5%) 83 (55%) 0.80 167 (54.2%)
Smoking, n (%) 13 (8.3%) 2 (1.3%) 0.003 15 (4.9%)
Mean total cholesterol, g/L (SD) 1.78 (0.56) 1.80 (0.52) 0.79 1.79 (0.54)
Mean LDL cholesterol, g/L (SD) 1.10 (0.53) 1.12 (0.49) 0.69 1.11 (0.51)
Mean HDL cholesterol, g/L (SD) 0.53 (0.21) 0.58 (0.22) 0.04 0.56 (0.22)
Triglycerides (g/l)* 0.92 (0.65-1.25) 0.84 (0.58-1.26) 0.41 0.88 (0.63-1.26)
Mean fasting glucose, g/L (SD) 1.57 (0.64) 1.48 (0.61) 0.25 1.53 (0.62)
Mean post-prandial glucose, g/l (SD) 1.96 (0.86) 1.78 (0.81) 0.04 1.87 (0.84)
Glucose control treatments
Oral agents, n (%) 114 (72.6%) 108 (71.5%) 0.83 222 (72.1%)
Insulin, n (%) 32 (20.4%) 46 (30.5%) 0.04 78 (25.3%)
Insulin and Oral agents, n (%) 8 (5.1%) 18 (11.9%) 0.04 26 (8.4%)
Blood pressure lowering medications, n (%) 65 (41.4%) 73 (48.3%) 0.22 138 (44.8%)
Statins use, n (%) 2 (1.3%) 1 (0.7%) 0.58 3 (1%)
Aspirin use, n (%) 2 (1.3%) 2 (1.3%) > 0.99 4 (1.3%)
* Values are Median (25th – 75th percentiles).
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In the overall population and in men however, this pat-
tern varied substantially.
Added value of combining sets of criteria
While the prevalence according to the NCEP-ATP III
definition was almost always lower than that according
to the IDF definition, combining the two sets of criteria
marginally improved the yield beyond that provided by
the IDF criteria alone in men (Figure 2), but not in the
overall population and in women. In some age subgroups
in women, the yield of the NCEP-ATP III criteria wasTable 2 Prevalence of the MS by age group and age standard
IDF criteria
Age groups Men Women P Total
<45 11 (52%) 9 (60%) 0.65 20 (56%
45-54 31 (62%) 47 (89%) 0.002 78 (76%
55-64 31 (54%) 37 (84%) 0.002 68 (67%
>= 65 18 (62%) 37 (95%) 0.001 55 (81%
Totala 91 (58%) 130 (86.1%) <0.001 221 (71.
Totalb 55.7% 72.1% 64.5%
Pc 0.78 0.02 0.03
a crude prevalence.
b age standardized prevalence.
c p-value for the difference by age group within a subgroup.higher than that for the IDF criteria, but their combin-
ation was not better than the NCEP-ATP III criteria
alone (Figure 2).
Discussion
Our results revealed high prevalence rates for the
metabolic syndrome using both diagnostic criteria but
much higher with IDF criteria. These rates were signifi-
cantly higher in women than in men, independently of
the criteria used. Concordance between both definitions
was low-to-average overall, and by gender, with the best
agreement observed in women. Eighty percents ofized prevalence
NCEP-ATP III criteria
Men Women P Total
) 9 (43%) 9 (60%) 0.31 18 (50%)
) 24 (48%) 43 (81%) <0.001 67 (65%)
) 22 (39%) 34 (77%) <0.001 56 (55%)
) 12 (41%) 33 (85%) <0.001 45 (66%)
7%) 67 (42.7%) 119 (78.8%) <0.001 186 (60.4%)
43.1% 68.1% 55.6%
0.80 0.28 0.21
Table 3 Agreement between IDF and NCEP-ATP III criteria
(Kappa statistic and 95% confidence interval)
Age group Men Women Total
Total 0.33 (0.19-0.47) 0.66 (0.50-0.82) 0.51 (0.41-0.61)
<45 years 0.62 (0.29-0.95) 0.72 (0.36-1) 0.67 (0.42-0.91)
45-54 0.48 (0.25-0.72) 0.71 (0.45-0.97) 0.61 (0.45-0.77)
55-64 0.07 (−0.17 to 0.32) 0.78 (0.55-1) 0.38 (0.20-0.56)
>= 65 0.34 (0.16-0.65) 0.19 (−0.21 to 0.58) 0.41 (0.19-0.64)
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teria were also classified within this category by the
NCEP-ATP III criteria, while NCEP-ATP III reclassified
the 20% remaining as having MS. Among those diag-
nosed with MS on the basis of the IDF criteria, the
NCEP-ATP III criteria confirmed the diagnosis of MS in
76% and reclassified 24% as not having MS. Combining
the two sets of criteria marginally improved the yield be-
yond that provided by the IDF criteria alone in men, but
not in the overall population and in women.
Few prevalence studies of MS have been conducted in
Africa, including in patients with diabetes [11]. Available
studies in the general population suggest an increasing
prevalence of MS with time, and collectively, haveFigure 1 Cross classification of the overall population according to th
MS+Presence of the metabolic syndrome.provided variable prevalence of MS ranging from low to
as high as figures reported in developed countries
[12,13]. Studies in people with diabetes, conducted in
large part in Nigeria have been based on different defin-
ition criteria and have also provided variables results.
One of the earliest was based on a sample of 218 type 2
diabetic outpatients receiving care at the Olabisi Ona-
banjo University Teaching Hospital in Nigeria from 1999
to 2001 [14]. In this study, Alebiosu and co-workers
found a prevalence rate of 25.5%, similarly among men
and women using the WHO criteria [14]. This preva-
lence was half the figure reported subsequently by Ade-
diran et al. [15] in a group of 408 type 2 diabetic
individuals at the University Teaching Hospital in Lagos
(Nigeria) applying the same definition criteria. The
prevalence rate in this study was 51% overall, 44% in
men and 56% in women [15]. This was still lower than
the 54–59% rate found by Isezuo and Ezunu among dia-
betic patients at the Usmanu Danfodiyo University
Teaching Hospital, Northwestern Nigeria in 2002
[16,17]. More recent studies in the same country have
found much higher prevalence rates: 63.6% in one study
based on IDF criteria [18], 62.5% in a second based on
the NCEP-ATP III criteria [19]; and 25.5% [20], 60%e two sets of criteria. MS- Absence of the metabolic syndrome;
Figure 2 Added value of combining the criteria overall and by
age groups.
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86% [23] in four studies from the same institution/inves-
tigators applying the Joint Interim Statement (JIS) cri-
teria [24]. Elsewhere in Africa, a 43% prevalence rate was
reported among 109 diabetic subjects in a tertiary care
diabetes clinic in Zimbabwe [25]; and rates of 66.8%,
85.5%, 74% among men and 87.1%, 79.7%, 93% among
women, according to the NCEP-ATP III, WHO and IDF
criteria, respectively, reported in Seychelles [26]. One
study compared the prevalent of MS based on IDF cri-
teria in African and White South African diabetics. Rates
of MS in this study were lower in Africans than in
Whites (46% vs. 74%) [27].
It follows from the above that prevalence rates found in
our study are among the highest so far reported in sub-
Saharan Africa. In general however, available reports from
Africa have mostly provided non-standardised prevalence
rates, which make direct comparison between studies less
reliable. Those reports have also been based on patients
with variable duration of diabetes, which can further in-
crease the disparities in the prevalence of MS between
studies. Indeed, the prevalence of components of MS is
likely to increase with increasing duration of diabetes. Our
prevalence rates compare with reports from various set-
tings around the world [28-30]. These similarities suggest
that the prevalence of the MS in people with type 2
diabetes seems to be independent of ethnic factors as the
prevalence rates remain high independent of the definition
criteria used.
While some studies in Africa have simultaneously ap-
plied different definition criteria for MS in the same
population, very few (and perhaps none in people withdiabetes) have directly compared the performance of dif-
ferent sets of criteria. One study in the general
population in rural South Africa found a good agreement
between the JIS criteria on one side and either the IDF
(kappa = 0.90) or the NCEP-ATP III (kappa = 0.77) on
the other side [31]. This agreement in major ways is
expected based on the fact that JIS more or less is just a
loose adaptation of the IDF and NCEP-ATP III criteria
[24]. Therefore virtually all patients with MS based on
either IDF or NCEP-ATP III criteria would also have MS
based on JIS criteria. The South African study however
did not directly compare the IDF and NCEP-ATP III cri-
teria [21]. In another study in Seychelles, the agreement
between the IDF, NCEP-ATP III and WHO criteria was
assessed overall and after exclusion of participants with
diabetes [14]. The agreement between the IDF and
NCEP-ATP III criteria was acceptable-to-good while
those for IDF vs. WHO and NCEP-ATP III vs. WHO
were only modest-to-acceptable, with in both cases only
a modest decrease in the point estimates upon exclusion
of participants with diabetes [14]. Both the South African
and Seychelles reports were all based on community
samples. In our hospital-based sample of treated diabetic
individuals with varying duration of the disease, we
found a low-to-acceptable agreement between the IDF
and NCEP-ATP III criteria. The agreement was particu-
larly poor among men. This is essentially explained by
differences in the contribution of abdominal obesity to
the definition of MS based on IDF or NCEP-ATP III cri-
teria [4,9].
Though both definitions identified a high prevalence of
the metabolic syndrome, combining the two sets of criteria
marginally improved the yield beyond that provided by the
IDF criteria alone in men, but not in the overall population
and in women. This may likely imply that using both defi-
nitions is of no value but instead a need to use a single and
adaptable definition to a particular population. The JIS cri-
teria published in 2009 aimed to achieve the above [24].
While the JIS Committee has agreed on the principle of a
definition with no obligatory component, it also explicitly
recognized two facts: 1) the abdominal obesity (waist cir-
cumference) component should be based on population-
specific threshold; 2) Most patients with type 2 diabetes
mellitus will have the metabolic syndrome by the JIS cri-
teria. There is currently no specific cut-off of waist circum-
ference for African Africans. Only one study has
attempted to define such a cut-off based on cross-sectional
data in South-Africa [31]. This cut-off has not yet been
validated for incident outcomes such as cardiovascular dis-
ease, and may therefore not be recommended for use in
other settings. The study however, suggests that African-
specific cut-off would likely be different from the Cauca-
sian cut-off currently recommended for use in Africa [31].
As predicted, studies that have applied the JIS criteria
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Africa [23]. All participants in our sample (data not
shown) qualified for MS based on the JIS criteria. This
suggests that, until the appropriate cut-offs for waist cir-
cumference specific to Africans are well defined; the appli-
cation of the JIS criteria in people with diabetes in this
setting would be of limited contribution.
Our study has some limitations that must be
accounted for when interpreting our findings. This was a
cross-sectional study conducted in a referral health
institution. Therefore, whether our findings reflect those
from a broader population with diabetes at the commu-
nity or primary care level is not known. However, virtu-
ally all studies on MS in Africa have been conducted in
tertiary care institutions, which make our findings com-
parable with those from other countries in the region.
Our study was based on patient files and registers, and
therefore we had no control on the quality of data used
in the study. It is possible that our estimates are impre-
cise due to measurement errors. While imprecision in
the levels of risk factors could affect the prevalence of
MS, it was less likely to affect the agreement statistics
between sets of criteria.
Conclusions
This study despite its limitations contributes to mapping
the prevalence of MS worldwide, particularly with
regards to people with diabetes in the African region.
Our findings emphasize the growing burden of lifestyle-
related non-communicable diseases in countries in epi-
demiological transition including Cameroon (24), con-
sistent with the ongoing epidemic of obesity worldwide.
This study to the best of our knowledge is the first in
sub-Saharan Africa describing relevant differences in the
application of IDF and NCEP–ATP III MS definitions in
people with type 2 diabetes and, moreover it opens
doors for further research to monitor the impact of the
adverse cardio-metabolic profile on future outcomes of
the patients. Just like exploring issues around the
characterization of MS in people with diabetes in this
setting, it is also relevant to explore avenues for improv-
ing the adoption of other approaches to risk stratifica-




This was a hospital-based cross-sectional study, conducted
at the Obesity Centre of the Yaounde Central Hospital.
This centre is the out-patient section of the endocrinology
service of the same health facility. The study setting has
been described in details previously [33]. At the time this
study was conducted, the centre was staffed with 3 endo-
crinologists, one general practitioner, one dietician, a nurseeducator, a laboratory technician and 3 nurses. A weekly
day hospital handled the annual assessment of patients
with diabetes at the centre. Activities performed as part of
the day hospital include: medical consultation, therapeutic
education, nutritional education, electrocardiogram,
fundus oculi, biological exams including fasting and
postprandial glycaemia, glycated haemoglobin, lipid profile
(high density lipoprotein, triglycerides, total cholesterol,
calculated low density lipoproteins), urine multistix, urea,
creatinine and uric acid levels, microalbuminuria. Low
density lipoproteins levels are calculated using Friedewalds
formula as follows: LDL-cholesterol = total cholesterol –
HDL-cholesterol – (triglycerides5) in grams per litre.
Study population
This included individuals with type 2 diabetes who had
participated in day hospital activities during the period
of 2006–2008. The study was approved by the adminis-
trative authorities of the hospital, acting institutional re-
view board. Data collected was handled in strict respect
of confidentiality. Patient identity was kept anonymous.
Data collection used a pre-designed data collection form
and included: age in years, sex, type and duration of diag-
nosed diabetes (in years), past medical history of hyperten-
sion and dyslipidaemia and treatments. Anthropometric
measurements included height (centimetres), weight (kilo-
grams) and waist circumference (centimetres). Systolic
(SBP) and diastolic (DBP) blood pressure were recorded in
mmHg. Biological data included the lipid profile (triglycer-
ides, high density lipoproteins, total cholesterol, and low
density lipoproteins in grams per litres) and blood glucose
levels (fasting and postprandial in grams per litre).
Definitions
Two definitions for the metabolic syndrome were applied
(IDF and NCEP-ATP III). The IDF 2005 definition [4]
was based on waist circumference ≥ 80 cm (women) ≥ 94
cm (men) and any two or more of any of the following:
fasting triglycerides ≥ 1.5 g/L or triglycerides lowering
drugs; fasting HDL cholesterol< 0.4 g/L (men), <0.5 g/L
(women); SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg, or
blood pressure lowering treatment; fasting plasma glu-
cose ≥ 1 g/l, or previously diagnosed type 2 diabetes. The
NCEP-ATP III definition [9] was based on three or more
of any of the following: waist circumference> 88 cm
(women) 102 cm (men); fasting triglycerides ≥ 1.5 g/L;
fasting HDL cholesterol <0.4 g/L (men), <0.5 g/L
(women); SBP ≥ 130 mmHg and/or DBF ≥ 85 mmHg;
fasting glucose ≥ 1.1 g/L.
Statistical analysis
The sample size was calculated with the use of the
command sskdlg [34] of the statistical software STA-
TAW. This calculation was based on an expected kappa
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40% by each set of criteria, a minimum envisaged differ-
ence of 0.11 between the kappa statistic and its lower
(or upper) 95% confidence interval. Based on these cri-
teria, the required sample size was 298 participants. The
sskdlg command as described in the STATAW manual is
based on the asymptotic variance presented by Fleiss,
Cohen and Everitt [35,36] and follows the procedure
outlined by Cantor [37]. Data were processed and ana-
lysed with the use of ExcelW 2007 and SAS/STATW v9.1
for Windows. Results are presented as percentages,
means, and medians. Groups comparison used the chi
square tests or equivalents for qualitative variables and
the t-test of Student and Analysis of the Variance
(ANOVA) or non-parametric equivalents as appropriate
for quantitative variables. The concordance between sets
of criteria for defining metabolic syndrome was assessed
with the use of the kappa statistic. Unless otherwise
indicated, a p-value <0.05 was considered significant.
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